STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1995, and the six-month period ended on that date. STAAR Surgical Company is a Delaware corporation headquartered in Monrovia, California, specializing in intraocular lenses (IOLs) and related surgical devices. As of August 4, 1995, the company had 12,772,176 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1995 | Six Months Ended July 1, 1994 |
|---|---|---|
| Total Revenues | $15,755,340 | $12,359,949 |
| Net Income | $3,417,505 | $2,457,830 |
| Gross Margin | 76.0% | 77.8% |
| Operating Income | $3,192,358 | $2,169,888 |
| Net Cash from Operating Activities | $2,346,618 | $609,503 |
| Cash and Cash Equivalents (End of Period) | $3,915,772 | $818,069 |
| Total Debt (Current + Long Term) | $4,311,722 | N/A (Derived from Balance Sheet) |
| Current Ratio | 3.1:1 | 3.4:1 (Dec 30, 1994) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 27.5% to $15.8 million, driven primarily by expanding international sales in Europe, South Africa, and Australia, alongside continued U.S. market acceptance.
- Profitability: Net income rose 39.1% to $3.4 million. Earnings per share (fully diluted) increased from $0.19 to $0.26.
- Cost Structure: Cost of Sales as a percentage of revenue increased to 24.0% from 22.2%, attributed to reduced product pricing in the domestic market. Conversely, General & Administrative expenses decreased as a percentage of revenue (14.0% vs. 20.4%) due to cost controls.
- Marketing Spend: Marketing and Selling expenses increased to 32.2% of revenue (from 29.0%) to support international staffing and advertising.
- Capital Allocation: The company utilized approximately $1.5 million of working capital to repurchase 176,500 shares of common stock during the first six months of 1995.
Outlook, Risks, and Contingencies
- Guidance: Management expects to remain profitable and believes future cash flow needs will be met by operations. Royalty income is expected to be minimal for the remainder of 1995.
- R&D Outlook: The company plans to maintain R&D spending at approximately 10% of revenues for product development and new research.
- Legal Contingencies:
- Alcon Litigation: On April 13, 1995, STAAR filed a lawsuit against Alcon Laboratories regarding breach of contract and specific performance related to Patent No. 4,573,998. This follows a countersuit by Alcon in Delaware regarding non-infringement.
- Allergan/Microtech Litigation: On July 31, 1995, a U.S. District Court ruled that STAAR's antitrust action against Allergan Medical Optics should proceed. The court also lifted a stay on discovery regarding Patent No. 4,681,102 (the "102 Patent"), confirming Microtech as the owner. STAAR believes this patent will be deemed invalid and unenforceable.
- Regulatory Approval: On April 3, 1995, the FDA approved STAAR's Ultraviolet ("UV") absorbing material for use in IOLs in the United States.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing litigation with Alcon Laboratories and Allergan Medical Optics.
- Confirm the sustainability of the 27.5% revenue growth rate, specifically regarding international market penetration.
- Monitor the trend in Cost of Sales, which rose to 24.0% of revenue due to domestic pricing reductions.
- Review the company's stock repurchase program progress (176,500 shares bought back; up to 1,000,000 authorized).
- Assess the commercial impact of the new FDA-approved UV-absorbing material on future product mix and margins.